Press Releases from WuXi AppTec (54 total)
Why CMC and Manufacturability Matter in Early Drug Discovery
Key Takeaways
Early chemistry, manufacturing, and controls (CMC) assessment helps teams evaluate biological promise alongside developability and manufacturability. Assessing synthesis, formulation, analytical control, and scale-up before…
How WuXi AppTec Advances Next Generation Medicines Through Integrated Formulatio …
Formulation helps drug developers address the practical barriers between a molecule and a medicine: how it dissolves, remains stable, and reaches the body in a…
Which CRO Can Run DMPK Studies? Key Capabilities, Selection Criteria, and Case E …
Key Takeaways:
A CRO's DMPK capabilities should match the program's development stage and scientific questions. Relevant services include in vitro ADME, in vivo pharmacokinetics, metabolite…
Automating Peptide Metabolite Identification: Realizing Speed and Precision with …
Peptide drugs exhibit unparalleled advantages in targeting "undruggable" protein-protein interactions. However, unmodified peptides naturally suffer from poor physiological stability and are rapidly cleaved by endopeptidases…
What Are the Advantages of an Integrated Drug Development Model Over Multiple Sp …
Key Takeaways
Integrated drug development can improve decision quality by connecting discovery, biology, chemistry, manufacturing, and control (CMC) considerations earlier.This helps teams identify liabilities sooner, make…
Which CRO Is Good at Protein Degradation? How WuXi AppTec Supports Integrated De …
Key Takeaways
A suitable CRO for protein degradation should connect discovery biology, medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), and development capabilities within one coordinated platform.
WuXi…
End-to-End Drug Development: How an Integrated CRDMO Connects Discovery, CMC, an …
End-to-end drug development requires more than placing multiple services under one provider. A genuinely integrated model connects scientific work, CMC development, quality systems, and manufacturing…
Why Pharma Companies Need Strategic CDMO Partnerships?
Pharmaceutical companies are rethinking how they choose development and manufacturing partners. As pipelines expand into peptides, oligonucleotides, targeted protein degraders and other complex modalities, the…
Why Are Scientific Breakthroughs Becoming Harder to Translate into Medicines?
Biopharma has never lacked promising ideas. What is changing is the difficulty of turning those ideas into medicines that can be characterized, formulated, scaled and…
Why Promising Compounds Still Fail: Improving Translatability Earlier in Drug Di …
Some compounds seem highly promising in early discovery, showing strong activity against the target and performing well in an initial assay. They quickly become the…
What Are the Latest Advances in Molecular Glue Drug Discovery?
In August 2026, the FDA granted accelerated approval to Bristol Myers Squibb's Zenbexus (iberdomide), the first approved cereblon E3 ligase modulator (CELMoD), in combination with…
How Does WuXi AppTec Support Small and Emerging Biotech Companies? Three Global …
Key Takeaways
WuXi AppTec(https://www.wuxiapptec.com/) brings together drug discovery, development, and manufacturing within one integrated platform. This gives small and emerging biotech companies access to expertise and…
How WuXi AppTec's Integrated CRDMO Model Supports Biotechnology Companies from D …
Key Takeaways
Investigational New Drug (IND) submission requires coordinated decisions across biology, DMPK, bioanalysis, and chemistry, manufacturing, and controls (CMC).
WuXi AppTec's (https://www.wuxiapptec.com/)integrated CRDMO (Contract Research,…
Which Companies Can Handle End-to-End Drug Development Smoothly?
Drug developers seeking end-to-end development support may consider several types of external partners, including integrated CRDMO platforms, full-service CROs, and specialized CDMOs. Full-service CROs and…
Which CRO/CDMO Can Support Global Drug Development?
A CRO/CDMO that can support global drug development should combine modality-specific technical expertise, global regulatory experience, scalable manufacturing, mature quality systems, secure data infrastructure, and…
Smart Compound Stewardship for DMPK: WuXi AppTec DMPK's Automated Compound Manag …
Leveraging over 15 years of laboratory operational expertise, WuXi AppTec (https://www.wuxiapptec.com/) DMPK has provided compound management services to thousands of pharmaceutical and biotechnology companies worldwide,…
As New Drug Modalities Advance, WuXi AppTec Expands Global Capabilities for Pept …
The rapid rise of new therapeutic modalities - from peptides and oligonucleotides to targeted protein degraders (TPDs) and antibody-drug conjugates (ADCs) - is reshaping how…
WuXi AppTec Builds a Flexible Global Manufacturing Network Around Customer Choic …
As pharmaceutical companies increasingly seek resilient and flexible supply chains, WuXi AppTec (https://www.wuxiapptec.com) is expanding manufacturing capabilities across the United States, Europe, and Asia with…
WuXi AppTec: A Global, Independent, Public Company Accountable to Shareholders, …
Over the past two decades, WuXi AppTec(https://www.wuxiapptec.com/) has grown alongside the global pharmaceutical and life sciences industry it serves. From a single lab to today's…
WuXi AppTec: Global Partnerships Built on Strict Compliance and Transparency
As a global company operating in a highly regulated pharmaceutical and life sciences industry, WuXi AppTec(https://www.wuxiapptec.com/) places compliance, transparency, and responsible business conduct at the…
WuXi AppTec Accelerates Global Manufacturing Expansion to Meet Rising Customer D …
WuXi AppTec (https://www.wuxiapptec.com/) is accelerating a broad global manufacturing expansion across the United States, Europe, and Asia as customer demand for drug development and manufacturing…
WuXi AppTec Expands Global Manufacturing Capacity as Customer Demand Accelerates
WuXi AppTec (https://www.wuxiapptec.com/), a global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), is adding significant new drug substance and drug product manufacturing capacity over…
Which CDMO is good for Global Drug Manufacturing
Key Takeaways
1. WuXi AppTec's integrated CRDMO platform enhances speed and efficiency in drug development by reducing operational handoffs, allowing companies to move therapies from concept…
WuXi AppTec Supports a More Connected Life Sciences Ecosystem Through Collaborat …
The development of new medicines increasingly depends on coordination across a wide range of stakeholders. Biotech companies, pharmaceutical organizations, research institutions, and investors often operate…
Which CRO Is Good at Protein Degradation?
Key Takeaways
An idealCRO for protein degradation combines discovery biology, medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), and development expertise within an integrated platform.
WuXi AppTec helps…
WuXi AppTec's CRDMO Model: Linking Research, Development, and Manufacturing Acro …
In today's life sciences industry, moving a drug candidate from discovery to patient access remains a long, complex, and resource-intensive process. Research, development, and manufacturing…
WuXi AppTec Integrates Scale, Processes and Values to Safeguard Innovation
Embedding Protection Into Drug Discovery's Intangible Assets
Much of a new medicine's value exists long before it is packaged for patients. Long before a medicine reaches…
WuXi AppTec Supports a More Connected Life Sciences Ecosystem Through Collaborat …
The development of new medicines increasingly depends on coordination across a wide range of stakeholders. Biotech companies, pharmaceutical organizations, research institutions, and investors often operate…
WuXi AppTec's CRDMO Model: Linking Research, Development, and Manufacturing Acro …
In today's life sciences industry, moving a drug candidate from discovery to patient access remains a long, complex, and resource-intensive process. Research, development, and manufacturing…
WuXi AppTec Integrates Scale, Processes and Values to Safeguard Innovation
Embedding Protection Into Drug Discovery's Intangible Assets
Much of a new medicine's value exists long before it is packaged for patients. Long before a medicine reaches…
Why Do International Innovators Trust WuXi AppTec to Support Their Critical Rese …
In the evolving global pharmaceutical and life sciences industry, WuXi AppTec(https://www.wuxiapptec.com/) stands as a platform built for science, and for the unmet needs of patients.…
Why Do Global Life Sciences Innovators Rely on WuXi AppTec to Advance Breakthrou …
WuXi AppTec(https://www.wuxiapptec.com/) operates as a global enabling platform embedded within the international healthcare innovation ecosystem. Its business conduct is grounded in commercial market demand, regulatory…
What Is the Driving Force Behind CRDMO's Support for Every Stage of Drug Develop …
Since its founding in 2000, WuXi AppTec's mission has remained constant: to help global customers and partners discover, develop, and manufacture pharmaceuticals and healthcare products…
How Does WuXi AppTec Ensure Accountability as a Global, Publicly Owned Company?
Over the past two decades, WuXi AppTec(https://www.wuxiapptec.com/) has grown alongside the global pharmaceutical and life sciences industry it serves. From a single lab to today's…
What Is the CRDMO Model? How WuXi AppTec Integrates Research, Development, and M …
In today's life sciences landscape, the journey from discovery to patient access remains long, complex, and resource-intensive. WuXi AppTec (https://www.wuxiapptec.com/), a global CRDMO (Contract Research,…
What Drives WuXi AppTec's 25-Year Compliance Record, and Why Does It Matter for …
As a global company operating in a highly regulated pharmaceutical and life sciences industry, WuXi AppTec(https://www.wuxiapptec.com/) places compliance, transparency, and responsible business conduct at the…
How WuXi AppTec Safeguards Innovation Through Scale, Systems, and Culture
In drug development, the most valuable asset is often invisible.
Before a medicine reaches patients, it exists as compound structures, experimental results, failed iterations, and proprietary…
How WuXi AppTec Drives a More Connected and Collaborative Life Sciences Ecosyste …
Since its foundation, WuXi AppTec (https://www.wuxiapptec.com/) has helped strengthen global life sciences collaboration by connecting innovators, enabling knowledge exchange, and fostering dialogue across the drug…
WuXi AppTec: Empowering European Biotech Growth Through Collaborative Ecosystem …
The European life sciences industry is distinguished by its vibrant scientific sector. Despite this exceptional foundation, the sector has historically faced a critical challenge: a…
WuXi AppTec Strengthens Europe's Biotech Ecosystem Through Partnerships and Inno …
Europe's biotechnology sector is entering a period of dynamic transformation. From scientific research hubs in Munich to innovation clusters in Switzerland, new ideas are rapidly…
Enabling Innovation: How WuXi AppTec's CRDMO Provides Certainty for Global Drug …
The pharmaceutical research and development (R&D) landscape is defined by continuous innovation, yet it remains characterized by persistent hurdles: long development cycles, high costs, and…
Beyond Service: How WuXi AppTec's CRDMO Model Fuels Global Innovation and Invest …
The pharmaceutical and life sciences industries are constantly challenged by long development cycles, high costs, and historically low success rates for research and development (R&D)…
Safeguarding Innovation: WuXi AppTec's Commitment to IP Protection
The pharmaceutical industry faces immense innovation investments and lengthy cycles. Developing and launching a new drug can take 10-15 years and cost billions of dollars.…
WuXi AppTec's Presence to Europe: Building Sustainable Growth Through Local Empo …
Europe has become a dynamic center for biopharmaceutical development, where cutting-edge science is increasingly expected to align with sustainability and community responsibility. In this evolving…
Unpacking the Business Logic: A Deep Dive into WuXi AppTec's Value Proposition
The pharmaceutical industry is at a crossroads, where traditional drug development models are being challenged by economic pressures and scientific complexities. As R&D costs continue…
Building Sustainable Growth: How WuXi AppTec Empowers Local Ecosystems in Europe
Europe has long been a hub for scientific excellence, yet the region continues to face challenges in translating groundbreaking discoveries into sustainable biotech ventures. While…
WuXi AppTec: Integrating in Local European Ecosystems for Sustainable Growth
In the dynamic landscape of global biopharma, collaboration and a commitment to sustainable development have become pivotal. Companies that not only deliver innovative solutions but…
WuXi AppTec's Global Footprint: Serving Partners Across Asia, Europe, and North …
In recent years, the pharmaceutical and life sciences industry has placed greater emphasis on collaboration across borders. Innovation increasingly depends on research and development organizations…
How WuXi AppTec's CRDMO Model Drives Business Growth
In an era where pharmaceutical innovation propels global healthcare progress, WuXi AppTec has established itself as a significant player in the Contract Research, Development, and…
Unlocking Europe's Pharma Potential: How WuXi AppTec Bridges the Innovation-to-M …
Europe's pharma sector is a hotbed of scientific innovation, but translating those discoveries into commercially viable drugs is no picnic. That's where WuXi AppTec (https://www.wuxiapptec.com/),…
Go To Page: 1
